NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on developing broad-spectrum antiviral nanomedicines, announced it has entered into a securities purchase agreement with a single healthcare institutional investor for a registered direct offering expected to generate approximately $6 million in gross proceeds. The offering includes 3,571,429 shares of common stock (or equivalents) at $1.68 per share, along with a concurrent private placement of Series A and Series B warrants to purchase up to 3,571,429 shares each, with exercise prices of $1.75 and $2.00 per share, respectively. The Series A warrants are exercisable six months after issuance and expire in two years, while the Series B warrants are exercisable after six months and expire in 5.5 years.
The closing is expected on or about Nov. 12, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is acting as sole placement agent. Proceeds from the offering will be used for working capital and general corporate purposes, according to the company's press release. The full press release is available at https://ibn.fm/neQChA.
This capital infusion comes as NanoViricides prepares to advance its lead drug candidate, NV-387, into Phase II human clinical trials. NV-387 is a broad-spectrum antiviral drug designed to treat respiratory viral infections such as RSV, COVID-19, Long COVID, and influenza, as well as MPOX/smallpox infections. The company is also developing NV-HHV-1 for shingles and other candidates targeting herpes, viral eye diseases, HIV, hepatitis C, rabies, dengue, and Ebola.
NanoViricides' technology is based on proprietary nanomedicine platforms licensed from TheraCour Pharma, Inc. The company holds exclusive, sub-licensable field licenses for several antiviral drugs. According to the company's website, NanoViricides has focused on creating special purpose nanomaterials that mimic host cell receptors to bind and neutralize viruses.
The offering provides a financial cushion as the company navigates the lengthy and capital-intensive drug development process. As with all pharmaceutical development, there is no assurance that any of NanoViricides' candidates will demonstrate sufficient efficacy or safety for clinical use. However, the company remains committed to advancing its pipeline, with additional research ongoing for coronaviruses, poxviruses, and enteroviruses.
This news is significant for investors tracking NNVC, as it provides the company with additional runway to achieve key clinical milestones. Latest updates on NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
